Recent news includes corporate leadership changes, patent developments, and business strategy updates relevant to PetVivo Holdings, Inc.

• PetVivo Holdings named Garry Lowenthal as CFO in March 2024 [N1].
• The company received a notice of allowance for a key patent application in January 2024 [N1].
• PetVivo Holdings has been advised to manage its cash resources prudently as of October 2022 [N1].
• Recent news coverage includes market and economic factors such as commodity prices and stock market trends, though not directly related to PetVivo’s business [N1].

PetVivo’s lead product, Spryng®, offers a novel approach to managing osteoarthritis in companion animals by addressing underlying joint tissue deterioration with a bio-integrative scaffold. The product’s demonstrated safety, efficacy, and multi-month duration of effect provide a potential alternative to symptom-focused treatments with side effects. The company’s broad patent portfolio and proprietary manufacturing processes protect its technology and support scalability. Recent clinical studies and licensing agreements expand the product’s validation and market reach. Distribution partnerships with established veterinary wholesalers facilitate access to licensed veterinary practices. The company’s pipeline of 17 therapeutic devices and plans for in-licensing human medical device products for veterinary use indicate potential for product line expansion. Financial resources and manufacturing capacity support ongoing commercialization efforts.

PetVivo operates in a competitive veterinary medical device market with established animal health companies and emerging players developing alternative treatments. The company has incurred significant net losses, reflecting ongoing investment in commercialization and clinical studies. Distribution agreements with major veterinary wholesalers have been terminated or transitioned, requiring the company to establish new sales channels. Regulatory requirements and the need for additional clinical validation may delay broader adoption. The company’s reliance on proprietary technology and trade secrets may face challenges from competitors or patent circumvention. Market acceptance of Spryng® and other products depends on veterinarian adoption and reimbursement dynamics. Limited financial resources and the need to manage cash prudently present operational risks.

PetVivo’s competitive advantages stem from its proprietary biomaterials technology, protected by a portfolio of issued patents, patent applications, and trade secrets covering compositions, manufacturing processes, and applications. The protein-based biomaterials simulate natural tissue components, offering enhanced biocompatibility and integration compared to synthetic alternatives. The company’s patented scalable manufacturing process in ISO-certified facilities supports consistent, high-quality production with minimized risks. Its lead product, Spryng®, addresses an unmet need in veterinary osteoarthritis treatment by targeting underlying joint deterioration rather than just symptoms, differentiating it from traditional therapies. Established distribution partnerships with leading veterinary wholesalers and licensing agreements further support market access. The combination of intellectual property protection, manufacturing capabilities, and targeted product applications creates barriers to entry and supports differentiation in the veterinary medical device market.

• Market Adoption Risk: The success of Spryng® and other products depends on acceptance by veterinarians and pet owners, which may be influenced by clinical study outcomes, competitive alternatives, and pricing.
• Regulatory and Compliance Risk: Although Spryng® is classified as a veterinary medical device not requiring FDA pre-market approval, other products in the pipeline may face regulatory hurdles that could delay commercialization.
• Financial Risk: The company has reported net losses and must manage cash and investments carefully to fund operations, clinical studies, and manufacturing expansion.
• Distribution and Sales Channel Risk: Termination of previous exclusive and non-exclusive distribution agreements requires the company to establish and maintain effective sales channels to reach veterinary practices.
• Intellectual Property Risk: While the company holds patents and trade secrets, there is risk of patent challenges, infringement, or competitors developing alternative technologies.

• PetVivo Holdings, Inc. is an emerging biomedical device company focused on manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals, primarily companion animals such as cats, dogs, and horses [S1].
• The company has a pipeline of 17 products for treatment of animals and humans, protected by a portfolio of 10 issued patents (6 U.S. and 4 foreign), 2 U.S. patent applications, and 6 proprietary trade secrets [S1].
• PetVivo's lead product is Spryng® with OsteoCushion® Technology, a veterinarian-administered intra-articular injection for managing lameness and joint afflictions such as osteoarthritis in dogs and horses, commercialized since Q2 fiscal 2022 [S1].
• Spryng® is a veterinary medical device composed of biocompatible, insoluble particles mimicking natural cartilage, designed to provide a bio-integrative scaffold in affected joints to restore joint mechanics and improve biomechanics and mechanical homeostasis [S1].
• Osteoarthritis affects approximately 14 million dogs and 1 million horses in the $11 billion companion animal veterinary care and product sales market [S1].
• Current treatments for osteoarthritis in animals mainly address symptoms (e.g., NSAIDs) but have side effects and do not halt joint degeneration; Spryng® addresses underlying cartilage deterioration and synovial fluid loss with minimal adverse side effects reported [S1].
• Spryng® is administered via standard intra-articular injection, can treat multiple joints simultaneously, and typically lasts at least 12 months with a cost of approximately $600 to $900 per joint [S1].
• The company initially had an exclusive distribution agreement with MWI Veterinary Supply Co. for Spryng® in the U.S. starting June 2022, which transitioned to non-exclusive in January 2024 and was mutually terminated in March 2025 [S1].
• PetVivo entered into a non-exclusive distribution agreement with Covetrus North America, LLC in December 2023, which was mutually terminated in February 2025 [S1].
• In December 2024, PetVivo established new wholesale distribution partnerships with Vedco Inc. and Clipper Distributing, LLC, both leaders in veterinary product logistics and supply [S1].
• Spryng® is classified as a veterinary medical device by the FDA and does not require pre-market approval; it completed a safety and efficacy study in rabbits in 2007 and has treated over 2,000 horses and dogs [S1].
• The company completed a clinical trial with Colorado State University in March 2024, an equine tolerance study in March 2022, and canine clinical studies with Ethos Veterinary Health, with the first completed in October 2023 and the second ongoing [S1].
• Manufacturing occurs in an ISO 7 certified clean room facility in Minneapolis using a patented scalable self-assembly production process; a second ISO cleanroom facility is expected to be operational later in 2026 [S1].
• PetVivo signed an exclusive licensing agreement with VetStem, Inc. in February 2025 to market and sell their PrecisePRP product for canine and equine use, generating revenues in fiscal 2026 [S1].
• The company’s biomaterials are protein-based, simulating body tissues with components such as collagen, elastin, and heparin, designed for enhanced biocompatibility and tissue integration [S1].
• PetVivo’s intellectual property portfolio includes patents, patent applications, trademarks (including Spryng® and OsteoCushion®), trade secrets, and copyrights protecting formulations, manufacturing processes, and product documentation [S1].
• As of June 29, 2026, PetVivo has 22 employees and engages outside consultants for R&D, clinical development, regulatory, investor relations, and operations [S1].
• Financial snapshot as of March 31, 2026: cash and equivalents $28,891; short-term investments $150,000; current assets $1,859,921; current liabilities $1,377,292; current ratio 1.35; cash ratio 0.13; net loss $10,473,672; basic and diluted EPS -$0.38 [S1,S2].
• The company’s common stock and warrants were registered under Section 12(b) of the Exchange Act and began trading on Nasdaq Capital Market in 2021 but currently trade on OTCQX Best Market under symbols PETV and PETVW [S1].
• PetVivo’s business model includes commercialization and licensing of veterinary medical devices, with plans to expand product pipeline through acquisition or in-licensing of human medical device products for veterinary use [S1].
• The company’s products target a companion animal market with growing pet ownership and a significant market for veterinary care and products, including osteoarthritis treatment [S1].
• PetVivo’s distribution strategy evolved from exclusive to non-exclusive agreements with major distributors and now includes partnerships with wholesale distributors to reach licensed veterinary practices [S1].
• The company maintains a life science commercial insurance policy with $2 million coverage for products and operations [S1].
• Recent news includes the appointment of Garry Lowenthal as CFO in March 2024 and receipt of a notice of allowance for a key patent application in January 2024 [N1].